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gB,  glycoprotein B 
HAART, highly active antiretroviral therapy 
KSHV, Kaposi’s sarcoma-associated herpes virus 
 
KS,  Kaposi’s sarcoma 
 
MCD,  multicentric Castleman disease 
 
MMP,  matrix metalloproteinases 
 
MSM,  men who have sex with men 
PEL,  primary effusion lymphoma  
 
PT,  phosophotransferase 
 
TK,  thymidine kinase 
 
VEGF, vascular endothelial growth factor 
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Summary 
Human herpesvirus 8 (HHV-8, also known as Kaposi sarcoma-associated herpesvirus or 
KSHV) is the etiologic agent of Kaposi sarcoma (KS) and primary effusion lymphoma 
(PEL), as well as many cases of Castleman disease. Despite significant advances in 
understanding the biology and natural history of these diseases, current treatment options 
have important limitations, and strategies to prevent their development in high-risk 
individuals are lacking. This article reviews the scope of HHV-8-associated disease, as 
well as the efficacy of current treatment options. Finally, novel approaches to treatment 
and prevention are described, including antiviral agents, targeted molecular therapy, and 
a combination of these modalities.  
 
Summary Word Count: 100
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Introduction 
 The human herpesviruses are among the world’s most ubiquitous infections, with 
almost all eight viruses infecting the majority of the global population. While there is 
some heterogeneity in the prevalence of these infections in different populations, only 
one shows a curious pattern of both geographic and demographic restriction. Human 
herpes virus 8 (HHV-8, also known as KSHV), was first identified as the etiologic agent 
of KS in 19941, and is now known to be prevalent in populations of men who have sex 
with men (MSM), as well as persons from the Southern Mediterranean, Middle East, 
Africa, and parts of South America and Asia2-5. 
 The reason for these distinct “pockets” of infection has not been well-
characterized. Epidemiologic and virologic data suggest that HHV-8 is transmitted 
predominantly through saliva6-9, similar to other human herpesviruses such as HSV-1, 
EBV, CMV, and HHV-6. It has been hypothesized that the relative restriction of HHV-8 
infection may be attributable to differences across populations in susceptibility to 
infection, control of viral replication at mucosal sites, and/or behavioral, biologic or 
infectious co-factors for acquisition. 
Prevalence of HHV-8-associated Disease 
 Infection with HHV-8 is most frequently asymptomatic10, but may progress to one 
of three neoplastic or lymphoproliferative disorders: KS, multicentric Castleman disease 
(MCD), or PEL11. The burden of HHV-8-associated disease is greatest in areas where 
HHV-8 infection is endemic12. However, while HHV-8 infection is required for 
development of KS, PEL or some forms of MCD, it is not likely to be sufficient. The 
presence of co-factors such as immunosuppression may enhance progression to disease13, 
and therefore there are clear disparities between the prevalence of HHV-8 infection and 
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the incidence of KS. For example, countries in Africa have among the highest incidence 
of KS in the world, but the incidence varies widely even in countries with a similar 
seroprevalence of HHV-8 and HIV infection (Figure 1). 
 KS is the commonest HHV-8-associated disease. In the height of the HIV 
epidemic, 1 in 5 HIV-infected persons in the USA developed KS13, though the incidence 
has dropped dramatically with the introduction of highly active antiretroviral therapy 
(HAART)14. Today, KS remains the most frequent malignancy in persons with HIV in 
the USA14. In many parts of Africa, KS is the most common cancer in the entire 
population12, and KS likely accounts for 1% of all cancers in resource-poor areas15. MCD 
and PEL remain relatively rare complications of HHV-8 infection. No comprehensive 
registry tracks the incidence of these diseases, and thus their frequency in the population 
is difficult to ascertain. It is estimated that less than 10,000 people are afflicted with 
MCD in the USA16, with even fewer cases of PEL under medical care.  
Efficacy and Limitations of Current Treatment Strategies 
 Despite significant progress over the past decade in understanding the 
pathophysiology of HHV-8-assocaited disease, treatment of these diseases today remains 
both toxic and incompletely efficacious. Response to HAART alone in persons with KS 
depends on the burden of preexisting disease; one metaanalysis found that 81% of 
persons without advanced KS experienced a complete response to HAART, but only 5 
cases of response to HAART alone could be documented in the medical literature among 
persons with more advanced KS17. A recent examination of persons who developed KS in 
the era of HAART in Seattle, Washington, found that half remain with persistent disease 
in the 3 years after diagnosis, despite treatment with HAART and chemotherapy18. The 
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vast majority of patients with KS, MCD or PEL will be co-infected with HIV, and control 
of HIV infection is an essential component of their care. No studies have documented 
responses in MCD or PEL with HAART alone. These data suggest that in MCD and 
PEL, as well as cases of advanced KS, treatment with HAART alone is unlikely to be 
sufficient.  
For patients requiring adjunctive therapy to HAART, the mainstay of current 
treatment is conventional chemotherapy. The use anthracyclines, antimitotic agents, 
microtubule stabilizers, or other chemotherapeutic agents alone or in combination for the 
treatment of KS have been shown in small clinical trials to result in response rates 
ranging from 25 to 88%19. Response varies with burden of disease, associated co-
morbidities, and control of underlying immunodeficiency when applicable. Also, it is 
important to note that many who “respond” to conventional chemotherapy will still have 
residual disease. Considerably less information is available regarding the treatment of 
MCD and PEL. In small case series, treatment of these diseases with conventional 
chemotherapy has been associated mostly with short-lived responses and high 
mortality16,20. 
Therapies Under Investigation 
 The limited response rates and significant toxicity seen with conventional 
adjunctive chemotherapy have spurred investigators to search for novel therapeutics for 
the treatment and prevention of HHV-8-associated disease.  
Antiviral Therapy 
 In each of the HHV-8-associated diseases, ongoing viral replication plays a key 
role in the development or sustenance of disease. The presence of replicating HHV-8 in 
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the peripheral blood has been shown to be one of the strongest predictors for the 
development of KS21-24, and in vitro work has revealed that a small amount of lytic HHV-
8 infection is required for the initiation and maintenance of KS tumors25. MCD is 
characterized by episodic reactivation of HHV-8 replication, accompanied by high levels 
of HHV-8 in the peripheral blood26 and an almost exclusively lytic viral gene program27. 
PEL falls somewhere between KS and MCD in the spectrum of lytic replication27. These 
observations imply that antiviral therapy aimed at abrogating HHV-8 replication may 
have a role in the prevention or treatment of HHV-8-associated disease. 
In 1978, a safe and effective compound was developed with considerable activity 
against the human herpesviruses28. In the subsequent three decades, a series of DNA 
synthesis inhibitors were developed with variable activity against each of the 8 human 
herpesviruses29. Data supporting the efficacy of antiviral medications in suppressing 
HHV-8 replication come from both basic science and observational studies. 
The herpesvirus DNA synthesis inhibitors rely on the ability of a nucleoside 
analogue to be incorporated into a growing viral DNA chain. The different antiherpetic 
antivirals differ in their mechanism of action. Aciclovir, penciclovir, famciclovir, and 
ganciclovir all are phosphorylated by the herpesvirus thymidine kinase (TK) and/or UL97 
phosphotransferase30, though each herpesvirus enzyme may have a different affinity for 
each nucleoside analogue. Foscarnet and cidofovir both work independently of the 
herpesvirus TK /UL97; the former acts directly on the pyrophosphate binding site of the 
DNA polymerase while the latter is diphosphorylated by cellular enzymes.  In the first set 
of analyses to determine whether any of the current antiviral agents would be active 
against HHV-8, it was found that the HHV-8 TK and PT share homology with those in 
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other human herpesviruses, and that they are capable of phosphorylating ganciclovir31. 
Subsequently, a set of novel experiments were designed to test the antiviral susceptibility 
of HHV-8 in vitro. These new methods were required because the virus does not produce 
a cytopathic effect in culture, obviating the traditional “gold standard’ for susceptibility 
testing, the plaque reduction assay. Though these experiments differed in their 
methodology, most measured the degree to which a given antiviral would reduce the 
production of HHV-8 lytic gene products (either viral DNA or lytically-expressed 
proteins) when added to a cell culture containing an immortalized, latently-infected 
HHV-8 cell line induced to lytic replication. The results were uniformly consistent in that 
ganciclovir, foscarnet and cidofovir were the only agents with activity against HHV-832-
36. HHV-8 research is also hampered by the lack of a facile animal model, but productive 
infection may be established in immunocompromised mice, and this infection is blocked 
by administration of ganciclovir immediately after inoculation with HHV-837. 
Evidence supporting the efficacy of antiviral medication in the prevention or 
treatment of HHV-8-associated disease in humans is found either in retrospective studies 
or case series.  Two separate retrospective studies found that the incidence of KS was 
significantly reduced among persons who had received foscarnet or ganciclovir for CMV 
retinitis, but no reduction in KS was seen among users of aciclovir38,39. Similarly, a study 
investigating the efficacy of systemic ganciclovir for the treatment of CMV retinitis in 
AIDS patients found substantial reductions in the incidence of KS among persons treated 
with the drug, though this outcome was a secondary endpoint and no measurements of 
HHV-8 replication were obtained40.   
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In the first and only clinical trial to date to evaluate the effect of antiviral 
medication on HHV-8 replication, 26 HHV-8 infected men (including 16 with HIV and 
10 without) were randomized to either oral valganciclovir, 900 mg daily,  or placebo once 
daily for 8 weeks41. After a 2-week washout period, participants were randomized to the 
opposite treatment arm for an additional 8 weeks. Oral swabs were collected for the 
quantification of HHV-8 DNA  by PCR daily throughout the 18-week study. The use of 
valganciclovir was associated with a 46% reduction in oral HHV-8 replication (Figure 2), 
an effect that was found to be independent of the reduction in CMV replication.  
Only one trial has evaluated the use of antiviral medication for the treatment of 
KS, finding that cidofovir was ineffective by itself for the treatment of both epidemic and 
classic KS42. Interferon-alpha, which has both antiviral and immunomodulatory 
properties, however, may find a role as adjunctive therapy in persons with advanced KS. 
Five (38%) of 13 patients with epidemic KS responded to interferon-alpha 2b in 
conjunction with HAART43.  
Although KS is more common, it might be expected that the HHV-8-associated 
diseases which are characterized by more extensive viral replication would be the best 
candidates for treatment with antiviral therapy. Successful treatment of PEL, either alone 
or with adjunctive chemotherapy, immunotherapy, or HAART, has been described to 
date with both ganciclovir44,45 and cidofovir44,46,47. Of note in some of these case series is 
a documented decline in HHV-8 viral load coinciding with administration of antiviral 
therapy44,46, and in one case, rebound with gaps in therapy44. Similar results have been 
observed in MCD patients treated with ganciclovir48,49, but failures have been reported 
with cidofovir50. Recent basic science data also find that it may be feasible to induce cells 
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latently-infected with HHV-8 to lytic replication with valproic51 or glycyrrhizic52 acid or 
bortezomib53, thereby “sensitizing” the tumor to antiviral therapy. Several clinical trials 
are currently enrolling patients to assess the efficacy of antiviral or inductive therapy in 
the treatment of HHV-8-associated disease  
Novel Chemotherapy 
 In the effort to make chemotherapy more effective and less toxic, great progress 
has been made in the past decade to target specific molecules involved in oncogenesis. 
Many HHV-8-associated conditions exhibit features making them ideal targets for 
molecularly-directed therapy54. 
 
Vascular Endothelial Growth Factor Inhibitors. KS is among the most vascular 
tumors, and the interactions between HHV-8 and the human vascular endothelial growth 
factor (VEGF) pathway are essential for tumorigenesis. VEGF receptors 2 and 3 are 
expressed in KS lesions55, and HHV-8 glycoproteins K1 and glycoprotein B (gB) 
increase the expression of VEGF and activate VEGF-R3 (respectively)56,57.  Clinical 
trials of early VEGF inhibitors, pentosan and tecogalan, were characterized by moderate 
toxicity and minimal efficacy58-60. A phase II study of IM862, an antiangiogenic 
compound which both inhibits VEGF formation and activates natural killer cells, showed 
that 36% of 44 patients with epidemic KS had at least a partial response61. Of note, no 
relationship between plasma VEGF levels and either administration of IM862 or tumor 
response could be identified, suggesting that either the effects were local or the drug 
worked in a manner independent of VEGF. A subsequent Phase III placebo controlled 
study, however, found the drug to be no more efficacious than HAART alone, suggesting 
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that the efficacy seen in the Phase II study may have been attributable to HAART use62. 
A Phase I study of a novel antisense oligonucleotide to VEGF (VEGF-AS) led to more 
dramatic decreases in VEGF plasma levels and a complete remission of KS in a patient 
who was refractory to chemotherapy and HAART, but dose-limiting toxicities were 
common63. 
 
Tyrosine Kinase Inhibitors. The observation that KS tumors express c-kit, the tyrosine 
kinase receptor for stem cell factor, suggested to some that HHV-8-associated 
malignancies may be treatable with c-kit inhibitors64. Limited experience with imatinib 
showed that 5 of 10 patients with epidemic KS displayed a partial response to the drug, 
though diarrhea limited the dose of imatinib which could be administered in 6 of 10 
participants65. Clinical trials are currently ongoing to examine the role of other c-kit 
inhibitors, such as sorafenib, in the treatment of KS. 
 
Monoclonal Antibody Therapy.  Deciphering the unique pathobiology of MCD has 
revealed two targets against which monoclonal antibody therapy could be effectively 
directed. Many of the signs and symptoms of MCD may be mediated by the production 
of viral IL-6, an analogue of the human cytokine which has been pirated by HHV-8. In an 
animal model, it has been shown that the expression of IL-6 in mice produces a disease 
which histologically and clinically resembles MCD66. Furthermore, high levels of IL-6 
are universally detected in patients with HHV-8-assocaited MCD26. Administration of a 
murine monoclonal antibody against IL-6 to a patient with MCD resulted in a dramatic 
resolution of symptoms and signs, but the illness rapidly returned after the infusion was 
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discontinued67. Subsequently, a humanized antibody to the IL-6 receptor was developed 
and was administered to 28 patients with the plasma cell variant of MCD in Japan68. Two 
of these participants were infected with HHV-8, and none had HIV. 12 (52%) of 23 
participants who had lymphadenopathy saw a significant reduction in the size of their 
lymph nodes at one year, and C-reactive protein levels normalized in 18 (64%) of 28. 
This study represents the largest clinical trial of person with MCD to date; the reasonable 
efficacy, and lack of serious adverse reactions, makes IL-6 receptor antagonists a 
promising choice for the treatment of MCD. The role of IL-6 in other HHV-8-associated 
diseases is less clear, but it is unlikely that these drugs will find indications in either PEL 
or KS. However, both MCD and PEL are primarily diseases of B lymphocytes. 
Consequently, monoclonal antibody therapy (rituximab) directed at CD20, expressed on 
all mature B-cells (Figure 3), has been used successfully in the treatment of both MCD 
and PEL69-77. 
 
Matrix Metalloproteinases. Matrix metalloproteinases (MMP) are overexpressed in KS 
tumors, and may play a role in oncogenesis by helping the tumor to invade the basement 
membrane. COL-3 is a topical MMP inhibitor which is similar in structure to 
tetracycline. In a Phase II clinical trial comparing 2 doses of COL-3, 41% of 75 patients 
responded to the lower (50 mg) dose78. Participants frequently discontinued using the 
drug, and photosensitivity was common. 
Summary 
In the quarter of a century since epidemic KS heralded the beginning of the HIV 
pandemic, much progress has been made in characterizing the frequency, spectrum, 
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pathophysiology and treatment of HHV-8-associated disease. The persistent global 
burden of KS, coupled with the few effective treatment options for MCD and PEL, argue 
for continued research on prevention and therapy for HHV-8-associated disease. Recent 
translational studies have identified several new targets for potential future therapies, 
including inhibitors of viral replication, cell signaling, inflammation, and angiogenesis, 
but the efficacy of these strategies can only be established through careful controlled 
clinical trials.
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Figures 
Figure 1. Prevalence of HHV-8 and HIV infection compared with the incidence of Kaposi sarcoma in countries of Africa, ranked according to their incidence of 
Kaposi’s sarcoma 
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Footnotes:  
 
HHV-8 Prevalence is estimated based on aggregates of studies since 1996 showing seroprevalence of HHV-8 in general population. 
HIV prevalence statistics are as of 2005 and taken from UNAIDS/WHO Global HIV/AIDS Online Database (available: 
http://www.who.int/GlobalAtlas/predefinedReports/EFS2006/index.asp). KS Age-Standardized Incidence Rates obtained from Cancer 
Incidence in Five Continents).  
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Figure 2. Effect of Valganciclovir on Human Herpesvirus 8 Oral Shedding, By HIV Status 
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Figure 3. Histopathology of Germinal Center in Hyaline Vascular Variant Multicentric Castleman Disease Stained with Antibodies to 
CD20 
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